Oncotarget

Errata:

Erratum: PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

PDF  |  How to cite

Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3

1 The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
2 Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia
3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia
4 Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America
5 Current address: Garvan Institute of Medical Research, Darlinghurst, Australia
6 Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia
* These authors contributed equally to this work

Published: January 21, 2020

This article has been corrected: During production, the 4th affiliation was mistakenly added to the name of the last author, Dr. Andrew S. Moore. The proper affiliation information is shown below.

Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3

1 The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia
2 Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia
3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia
4 Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America
5 Current address: Garvan Institute of Medical Research, Darlinghurst, Australia
6 Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia
* These authors contributed equally to this work

Original article: Oncotarget. 2019; 10:5755–5767. DOI: https://doi.org/10.18632/oncotarget.27206.

Amanda M. Smith1,4,*, Christine R.C. Zhang1,4,*, Alexandre S. Cristino1,6, John P. Grady1,5, J. Lynn Fink1 and Andrew S. Moore1,2,3

1 The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Australia

2 Oncology Services Group, Queensland Children’s Hospital, South Brisbane, Australia

3 Child Health Research Centre, The University of Queensland, South Brisbane, Australia

4 Current address: Washington University in Saint Louis, Saint Louis, Missouri, United States of America

5 Current address: Garvan Institute of Medical Research, Darlinghurst, Australia

6 Current address: Griffith Institute for Drug Discovery, Brisbane Innovation Park, Nathan, Australia

* These authors contributed equally to this work

Correspondence to:

Andrew S. Moore,email: andy.moore@health.qld.gov.au
J. Lynn Fink,email: l.fink@uq.edu.au

Keywords:

Received: RECEIVED_DATE     Accepted: ACCEPTED_DATE     Published: January 21, 2020